Insulet Corporation (PODD) FY2025 10-K Annual Report
Insulet Corporation (PODD) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 18, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Insulet Corporation FY2025 10-K Analysis
Business Overview
- • Core business in marketing and product training within healthcare, focusing on compliance with complex healthcare laws like Medicare, Medicaid, and anti-bribery statutes
- • Emphasis on advanced AI tool deployment and adherence to evolving global privacy, data protection, and AI regulations including EU AI Act by August 2026
- • Strategic focus on managing cybersecurity risks and potential data breaches amid increased reliance on cloud-hosted systems and AI infrastructure
- • Notable leadership changes in 2025 including new CEO and CFO, impacting talent retention and operational continuity
- • Elevated regulatory and compliance risks due to expanded data privacy laws (e.g., CCPA, CPRA), complex IT security challenges, and credit agreement restrictions affecting capital flexibility
Management Discussion & Analysis
- • Revenue $2,708.1M in 2025, up 30.7% YoY (+$636.6M); U.S. revenue $1,919.8M (+27.2%), International $754.3M (+44.1%)
- • Gross margin 71.6% in 2025 vs 69.8% in 2024; R&D expense 11.1% of revenue vs 10.6%; SG&A 43.0% vs 44.3%
- • Best segment: International Omnipod Products up $230.9M (44.1%); worst: Drug Delivery down 12.3% or $4.8M to $34.1M
- • Free cash flow $377.7M, up $72.4M; Capex $191.6M (+53%), share repurchase $59.6M in 2025, $300M planned in Q1 2026
- • 2026 outlook: Expected strong U.S. and International revenue growth from recurring sales and Omnipod 5 adoption; tariff risk if medical device exemptions eliminated
Risk Factors
- • Cybersecurity risk oversight primarily by NGR Committee with regular updates from CISO and strategic roadmap reviews
- • CISO reports to CTO, leading cybersecurity program including risk detection and continuous improvement in medical device manufacturing
- • CTO with 15+ years experience co-chairs Technology Risk Committee ensuring cybersecurity governance and remediation actions
- • No specific regulatory, geopolitical, operational, competitive, or financial risks detailed beyond cybersecurity governance
Insulet Corporation FY2025 Key Financial MetricsXBRL
Revenue
$2.7B
▲ +30.7% YoY
Net Income
$247M
▼ -40.9% YoY
Gross Margin
71.6%
▲ +185bp YoY
Operating Margin
17.5%
▲ +258bp YoY
Net Margin
9.1%
▼ -1107bp YoY
ROE
16.3%
▼ -1822bp YoY
Total Assets
$3.2B
▲ +3.3% YoY
EPS (Diluted)
$3.48
▼ -39.8% YoY
Operating Cash Flow
$569M
▲ +32.3% YoY
Source: XBRL data from Insulet Corporation FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Insulet Corporation
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.